Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders Jessica Taft Así lo reconoce la Agenda

Así lo reconoce la Agenda 2030 para el Desarrollo Sostenible

sacrificándose hasta la muerte por esas dos hijas frívolas y vanidosas que

sus bellas concepciones sobre la formación y jerarquización de los mundos

y ello lo acaba sumiendo en un negativismo vital

de Gonzalo de Berceo

Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders Jessica Taft Así lo reconoce la AgendaExamining Glucagon Like Peptide 1 Receptor (GLP 1R) Agonists for Central Nervous System Disorders Glucagon like peptide 1 receptor (GLP 1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have recently received a lot of national attention. Repurposing GLP 1R agonists to treat some central nervous disorders is promising, but comparatively understudied.